Abstract:Abstract Background S1P receptor (S1PR)1/5 modulators have been tested successfully in clinical development programs in ulcerative colitis (UC), leading to their FDA approval. They are believed to act through lymphocyte redistribution in peripheral lymphoid tissue and reduced numbers of circulating lymphocytes, but evidence from other organs suggests potential additional mechanisms of action. Methods A post-hoc analysis of the phase 3 trial of the S1PR1/5 modulator Ozanimod in patients with moderately to severely active UC was performed assessing an association of absolute lymphocyte count (ALC) with efficacy. Expression levels of S1PRs were analyzed in human intestinal tissues and primary cells using qPCR and/or immunohistochemistry (IHC). Effects of S1P, S1PR1/5 modulators and S1P1 knockdown on migration, proliferation, cytokine production, downstream signaling (immunoblot), tube formation of human intestinal microvascular endothelial cells (HIMEC) was evaluated. S1P and S1PR1/5 modulators were examined in a murine matrix plug angiogenesis model and with topical and systemic S1PR1/5 modulator therapy in dextrane sodium sulfate (DSS) colitis in vivo. Results Baseline ALC and relative or absolute ALC reductions were neither correlated with nor predictive of clinical or endoscopic outcomes. In murine DSS colitis topical therapy with a S1PR1/5 modulator ameliorated colitis but did not alter peripheral lymphocyte numbers. S1PR1 gene and protein expression was increased in UC and Crohn’s disease (CD) patients and predominantly expressed on HIMEC. S1P promoted HIMEC migration, proliferation, tube formation, IL-8 secretion, indicative of pro-angiogenic responses in vitro. Modulation of S1PR1/5 and knockdown of S1PR1 markedly inhibited these pro-angiogenic functions in the presence of high concentrations of S1P, but enhanced angiogenesis when low S1P concentrations were present. S1PR5 had no effect on angiogenesis. In the murine plug assay, S1PR1 induced angiogenesis. In acute DSS colitis, treatment of S1PR modulator by enema reduced blood vessels, but left lymphatics unaffected. Conclusion We present a novel mechanism of action of S1PR1 modulators in IBD intestinal tissue, potentially explaining a disconnect between ALC and efficacy observed in a post-hoc analysis of the phase 3 Ozanimod UC trial. The data presented suggest that S1P induced angiogenesis is attenuated by S1PR1 modulation in HIMEC from IBD patients when S1P levels comparable to blood were present. In the presence of S1P at concentrations consistent with lymph fluid angiogenesis was increased. Together with reduced numbers of circulating lymphocytes, this may contribute to efficacy of S1PR1 modulators in IBD patients.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the mechanism of action of S1P receptor 1 (S1PR1) modulators in inflammatory bowel disease (IBD), especially how these modulators affect intestinal angiogenesis and whether their impact on lymphocyte numbers is related to clinical efficacy. The background section mentions that S1PR1/5 modulators have been successful in clinical trials of ulcerative colitis (UC) and have been approved by the FDA. However, the mechanisms of action of these drugs may not be limited to reducing the number of circulating lymphocytes through lymphocyte redistribution, but may also involve additional mechanisms in other organs. To explore this issue, the research team conducted multiple experiments, including analyzing data from phase 3 clinical trials, evaluating the expression levels of S1PRs in human intestinal tissues and primary cells, detecting the effects of S1P and its receptor modulators on the migration, proliferation, tube formation, and cytokine production of human intestinal microvascular endothelial cells (HIMEC), and examining the effects of S1PR1/5 modulators on angiogenesis and DSS - induced colitis in mouse models. The research results show that the baseline absolute lymphocyte count (ALC) and its relative or absolute reduction have no significant correlation or predictive value with clinical or endoscopic results. In addition, in the mouse DSS - colitis model, local use of S1PR1/5 modulators can relieve colitis symptoms without changing the number of peripheral lymphocytes. The S1PR1 gene and protein are increased in patients with UC and Crohn's disease (CD), and are mainly expressed on HIMEC. S1P can promote HIMEC migration, proliferation, tube formation, and IL - 8 secretion, showing a pro - angiogenic response. The regulation of S1PR1/5 and the knockdown of S1PR1 significantly inhibited these pro - angiogenic functions under high - concentration S1P conditions, but promoted angiogenesis under low - concentration S1P conditions. S1PR5 has no effect on angiogenesis. In the mouse plug - in experiment, S1PR1 induced angiogenesis. In acute DSS - colitis, the administration of S1PR modulators by enema reduced the number of blood vessels but did not affect lymphatic vessels. In conclusion, this study reveals a new mechanism of action of S1PR1 modulators in the intestinal tissues of IBD patients, which may be one of the reasons for explaining the inconsistency between ALC and efficacy observed in the post - hoc analysis of the phase 3 Ozanimod UC trial. The study shows that when the S1P level is similar to that in the blood, S1P - induced angiogenesis is inhibited by S1PR1 regulation; while when the S1P concentration is similar to that in the lymph, angiogenesis is enhanced. These findings, together with the reduced number of circulating lymphocytes, may jointly contribute to the efficacy of S1PR1 modulators in IBD patients.

OP22 Topical Sphingosine-1-Phosphate (S1P) Receptor 1 Modulation Regulates Gut Angiogenesis in Inflammatory Bowel Diseases

PDE9 Inhibitor PF-04447943 Attenuates DSS-Induced Colitis by Suppressing Oxidative Stress, Inflammation, and Regulating T-Cell Polarization

Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management

ECCO Grant Dissecting the role of S1PR1 modulator in the mucosal regeneration of Ulcerative Colitis

Safety and efficacy of S1P receptor modulators for the induction and maintenance phases in inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials

Role of Sphingosine-1-phosphate Receptors in Vascular Injury of Inflammatory Bowel Disease.

The role of sphingosine-1-phosphate in the gut mucosal microenvironment and inflammatory bowel diseases

Design,Synthesis and Biological Evaluation of Potent and Selective S1PR1 Agonists for the Treatment of Ulcerative Colitis

Efficacy and Safety of Sphingosine 1-Phosphate Receptor Modulators for Ulcerative Colitis

Sa1796 Diet-Induced Secretion of Incretins is Regulated by Nutrients in the Stomach

P172 Spatial Transcriptomics Characterization of S1P Pathway Genes in Ulcerative Colitis and Crohn’s Disease Colon Tissues

Sphingosine 1-phosphate and inflammation.

The function of Sphingosine-1-phosphate receptor 2 (S1PR2) in maintaining intestinal barrier and inducing ulcerative colitis

Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis

P127 Sphingosine-1-Phosphate Receptor Blockade with Etrasimod alters Lymphocyte Trafficking in Crohn's Disease: Insights from High-Dimensional Phenotypic Mapping

S1PR1 inhibition induces proapoptotic signaling in T cells and limits humoral responses within lymph nodes

Dissecting the Therapeutic Mechanisms of Sphingosine-1-Phosphate Receptor Agonism during Ischaemia and Reperfusion

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

Oral Treatment with SEW2871, a Sphingosine-1-phosphate Type 1 Receptor Agonist, Ameliorates Experimental Colitis in Interleukin-10 Gene Deficient Mice.

[Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators]